QuantLogix ← TMO scorecard
📅 TMO Earnings Preview
Thermo Fisher Scientific, Inc.
Next report (est.)
September 14, 2026
Countdown
93 days
EPS growth YoY
+11.3%
Revenue growth YoY
+6.2%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 1, 2026 ±2.7% -2.0% over-priced
October 31, 2025 ±2.1% +2.0% over-priced
August 1, 2025 ±2.5% -1.0% over-priced
May 2, 2025 ±2.7% +0.9% over-priced
November 1, 2024 ±1.5% +2.1% under-priced
August 2, 2024 ±2.1% -1.0% over-priced
May 3, 2024 ±1.9% +0.2% over-priced
November 3, 2023 ±2.7% +1.6% over-priced
Across these reports, options implied an average ±2.3% move vs an actual average of 1.4% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $4.43 $11.0B $1.7B
Q4 FY2025 $5.21 $12.2B $2.0B
Q3 FY2025 $4.27 $11.1B $1.6B
Q2 FY2025 $4.28 $10.9B $1.6B
Live 5-factor engine read: Neutral · 39/100 Full scorecard →
Get alerted before every TMO report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on TMO before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Thermo Fisher Scientific, Inc. (TMO) reports in 93 days, with the next report estimated for September 14, 2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 1.4% on average — the market has systematically over-priced TMO's earnings risk. Fundamentals into the print: EPS up 11.3% year-over-year, revenue up 6.2%. QuantLogix's live 5-factor engine currently reads TMO as a neutral at 39/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →